United States - English - NLM (National Library of Medicine)

wg critical care, llc - cefazolin sodium (unii: p380m0454z) (cefazolin - unii:ihs69l0y4t) - cefazolin 500 mg - cefazolin for injection, usp is indicated for the treatment of the following serious infections due to susceptible organisms: respiratory tract infections: due to s. pneumoniae, klebsiella species, h. influenzae, s. aureus (penicillin-sensitive and penicillin-resistant), and group a beta-hemolytic streptococci. injectable benzathine penicillin is considered the drug of choice in treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cefazolin for injection, usp is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of cefazolin for injection, usp in the subsequent prevention of rheumatic fever are not available at present. urinary tract infections: due to e. coli, p. mirabilis, klebsiella species, and some strains of enterobacter and enterococci. skin and skin structure infections: due to s. aureus (penicillin‑sensitive and penicillin-resistant), group a beta‑hemolytic streptococci, and other strains of

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - cefazolin sodium, quantity: 1048 mg (equivalent: cefazolin, qty 1000 mg) - injection, powder for - excipient ingredients: - cephazolin sodium injection is indicated in the treatment of the following serious infections due to susceptible organisms: 1. respiratory tract infections due to s. pneumoniae, klebsiella species, h. influenzae, staph. aureus (penicillin-sensitive and penicillin-resistant), and group a beta-haemolytic streptococci. injectable benzathine penicillin is considered to be the drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cephazolin sodium is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of cephazolin sodium in the subsequent prevention of rheumatic fever are not available at present 2. gentinourinary tract infections due to esch. coli, pr. mirabilis, klebsiella species and some strains of enterobacter and enterococci. 3. skin and soft-tissue infections due to staph. aureus (penicillin-sensitive and penicillin-resistant) and group a beta-haemolytic streptococci and other strains of streptococci. 4. bone and joint infections due to staph. aureus. 5. septicaemia due to s. pneumoniae, staph. aureus (penicillin-sensitive and penicillin- resistant), pr. mirabilia, esch. coli and klebsiella species. 6. endocarditis due to staph. aureus (penicillin-sensitive and penicillin-resistant) and group a beta-haemolytic streptococci. appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cephazolin sodium.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - cefazolin sodium, quantity: 524 mg (equivalent: cefazolin, qty 500 mg) - injection, powder for - excipient ingredients: - cephazolin sodium injection is indicated in the treatment of the following serious infections due to susceptible organisms: 1. respiratory tract infections due to s. pneumoniae, klebsiella species, h. influenzae, staph. aureus (penicillin-sensitive and penicillin-resistant), and group a beta-haemolytic streptococci. injectable benzathine penicillin is considered to be the drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cephazolin sodium is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of cephazolin sodium in the subsequent prevention of rheumatic fever are not available. 2. gentinourinary tract infections due to esch. coli, pr. mirabilis, klebsiella species and some strains of enterobacter and enterococci. 3. skin and soft-tissue infections due to staph. aureus (penicillin-sensitive and penicillin-resistant) and group a beta-haemolytic streptococci and other strains of streptococci. 4. bone and joint infections due to staph. aureus. 5. septicaemia due to s. pneumoniae, staph. aureus (penicillin-sensitive and penicillin- resistant), pr. mirabilia, esch. coli and klebsiella species. 6. endocarditis due to staph. aureus (penicillin-sensitive and penicillin-resistant) and group a beta-haemolytic streptococci. appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cephazolin sodium.

Malta - English - Medicines Authority

pharmsol europe limited the victoria centre unit 2, lower ground floor, valletta road, mosta mst 9012 , malta - cefazolin sodium - powder for solution for injection/infusion - cefazolin sodium 1 g - antibacterials for systemic use

United States - English - NLM (National Library of Medicine)

orchid healthcare (a division of orchid chemicals and pharmaceuticals ltd.) - cefazolin sodium (unii: p380m0454z) (cefazolin - unii:ihs69l0y4t) - injection, powder, for solution - 10 g - cefazolin for injection is indicated in the treatment of the following serious infections due to susceptible organisms: respiratory tract infections due to s. pneumoniae, klebsiella species, h. influenzae, s. aureus (penicillin-sensitive and penicillin-resistant), and group a beta-hemolytic streptococci. injectable benzathine penicillin is considered to be the drug of choice in treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cefazolin for injection is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of cefazolin for injection in the subsequent prevention of rheumatic fever are not available at present. urinary tract infections due to e. coli, p. mirabilis, klebsiella species, and some strains of enterobacter and enterococci. skin and skin structure infections due to s. aureus (penicillin-sensitive and penicillin-resistant), group a beta-hemolytic streptococci, and other strains of streptococci.

United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - cefazolin sodium (unii: p380m0454z) (cefazolin - unii:ihs69l0y4t) - cefazolin for injection, usp is indicated for the treatment of the following serious infections due to susceptible organisms. respiratory tract infections: due to s. pneumoniae, klebsiella species, h. influenzae, s. aureus (penicillin-sensitive and penicillin-resistant), and group a beta-hemolytic streptococci. injectable benzathine penicillin is considered the drug of choice in treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cefazolin for injection, usp is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of cefazolin for injection, usp in the subsequent prevention of rheumatic fever are not available at present. urinary tract infections: due to e. coli, p. mirabilis, klebsiella species, and some strains of enterobacter and enterococci. skin and skin structure infections: due to s. aureus (penicillin-sensitive and penicillin-resistant), group a beta-hemolytic streptococci, a

United States - English - NLM (National Library of Medicine)

sagent pharmaceuticals - cefazolin sodium (unii: p380m0454z) (cefazolin - unii:ihs69l0y4t) - cefazolin for injection, usp is indicated for the treatment of the following serious infections due to susceptible organisms: respiratory tract infections: due to s. pneumoniae, klebsiella species, h. influenzae, s. aureus (penicillin-sensitive and penicillin-resistant), and group a beta-hemolytic streptococci. injectable benzathine penicillin is considered the drug of choice in treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cefazolin for injection, usp is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of cefazolin for injection, usp in the subsequent prevention of rheumatic fever are not available at present. urinary tract infections: due to e. coli, p. mirabilis, klebsiella species, and some strains of enterobacter and enterococci. skin and skin structure infections: due to s. aureus (penicillin-sensitive and penicillin-resistant), group a beta-hemolytic streptococci, and other strains of streptococci. biliary tract infections: due to e. coli , various strains of streptococci, p. mirabilis , klebsiella species, and s. aureus . bone and joint infections: due to s. aureus . genital infections: (i.e., prostatitis, epididymitis) due to e. coli , p. mirabilis , klebsiella species, and some strains of enterococci. septicemia: due to s. pneumoniae , s. aureus (penicillin-sensitive and penicillin-resistant), p. mirabilis , e. coli , and klebsiella species. endocarditis: due to s. aureus (penicillin-sensitive and penicillin-resistant) and group a beta-hemolytic streptococci. perioperative prophylaxis: the prophylactic administration of cefazolin for injection, usp preoperatively, intraoperatively, and postoperatively may reduce the incidence of certain postoperative infections in patients undergoing surgical procedures which are classified as contaminated or potentially contaminated (e.g., vaginal hysterectomy, and cholecystectomy in high-risk patients such as those older than 70 years, with acute cholecystitis, obstructive jaundice, or common duct bile stones). the perioperative use of cefazolin for injection, usp may also be effective in surgical patients in whom infection at the operative site would present a serious risk (e.g., during open-heart surgery and prosthetic arthroplasty). the prophylactic administration of cefazolin for injection, usp should usually be discontinued within a 24-hour period after the surgical procedure. in surgery where the occurrence of infection may be particularly devastating (e.g., open-heart surgery and prosthetic arthroplasty), the prophylactic administration of cefazolin for injection, usp may be continued for 3 to 5 days following the completion of surgery. if there are signs of infection, specimens for cultures should be obtained for the identification of the causative organism so that appropriate therapy may be instituted (see dosage and administration ). to reduce the development of drug-resistant bacteria and maintain the effectiveness of cefazolin for injection, usp and other antibacterial drugs, cefazolin for injection, usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. cefazolin for injection is contraindicated in patients with known allergy to the cephalosporin group of antibiotics.

United States - English - NLM (National Library of Medicine)

sagent pharmaceuticals - cefazolin sodium (unii: p380m0454z) (cefazolin - unii:ihs69l0y4t) - cefazolin for injection, usp is indicated for the treatment of the following serious infections due to susceptible organisms: respiratory tract infections: due to s. pneumoniae, klebsiella species, h. influenzae, s. aureus (penicillin-sensitive and penicillin-resistant), and group a beta-hemolytic streptococci. injectable benzathine penicillin is considered the drug of choice in treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cefazolin for injection, usp is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of cefazolin for injection, usp in the subsequent prevention of rheumatic fever are not available at present. urinary tract infections: due to e. coli, p. mirabilis, klebsiella species, and some strains of enterobacter and enterococci. skin and skin structure infections: due to s. aureus (penicillin-sensitive and penicillin-resistant), group a beta-hemolytic streptococci, and other strains of

United States - English - NLM (National Library of Medicine)

sagent pharmaceuticals - cefazolin sodium (unii: p380m0454z) (cefazolin - unii:ihs69l0y4t) - cefazolin for injection, usp is indicated for the treatment of the following serious infections due to susceptible organisms: respiratory tract infections: due to s. pneumoniae, klebsiella species, h. influenzae, s. aureus (penicillin-sensitive and penicillin-resistant), and group a beta-hemolytic streptococci. injectable benzathine penicillin is considered the drug of choice in treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cefazolin for injection, usp is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of cefazolin for injection, usp in the subsequent prevention of rheumatic fever are not available at present. urinary tract infections: due to e. coli, p. mirabilis, klebsiella species, and some strains of enterobacter and enterococci. skin and skin structure infections: due to s. aureus (penicillin-sensitive and penicillin-resistant), group a beta-hemolytic streptococci, and other strains of

New Zealand - English - Medsafe (Medicines Safety Authority)

multichem nz limited - cefazolin sodium 1.048 g equivalent to cephazolin 1 g;   - powder for injection - 1 g - active: cefazolin sodium 1.048 g equivalent to cephazolin 1 g